IMAGE IN CARDIOLOGY

DOI: 10.4244/EIJY15M02_01

Implantation of a novolimus-eluting bioresorbable scaffold with a strut thickness of 100 µm showing evidence of self-correction

Jens Wiebe1, MD; Timm Bauer1, MD; Oliver Dörr1, MD; Helge Möllmann2, MD; Christian W. Hamm1,2, MD; Holger M. Nef1*, MD

Practical concerns regarding poly-L-lactic acid (PLLA)-based bioresorbable scaffolds (BRS) are mostly related to the strut thickness of 150 µm. Implantation may cause more vessel injury as well as non-laminar flow and activation of platelet function. Furthermore, constraints of deliverability preclude BRS use in the presence of tortuosity or severe calcification. The PLLA-based novolimus-eluting DESolve® 100 scaffold (Elixir Medical Corporation, Sunnyvale, CA, USA) has a strut thickness of 100 µm. Complete degradation is achieved within two years. Furthermore, it has wider expansion ranges than other BRS and self-correction properties corresponding to nominal diameters, which can resolve minor malapposition.

In a mid-RCX stenosis, predilatation was performed with a non-compliant and a scoring balloon. Thereafter, a 2.5/28 mm BRS was implanted. Optical coherence tomography (OCT) revealed malapposition with a maximum vessel-wall distance of 0.33 mm and further edge dissection. Thus, a second 2.5/14 mm BRS was implanted distally. Another OCT run revealed a reduction of malapposition of the first BRS within 15 minutes: the vessel-wall distance decreased from 0.33 mm to 0.25 mm, and the minimal scaffold area increased from 3.94 mm2 to 4.28 mm2 (Figure 1). Nevertheless, malapposition was still present and post-dilatation was implemented with a non-compliant balloon. Final OCT confirmed a satisfactory result. The Online Appendix, Online Figure 1, Online Figure 2 and Moving image 1-Moving image 6 can be found online. The in vitro scaffold cross-sectional area under nominal pressure for the 2.5 mm DESolve 100 is 4.91 mm2, thus further self-correction is presumable. Self-correction appears reasonable especially in the presence of thrombi. Additional investigations will certainly be required for a conclusive proof-of-concept.

Figure 1. Evidence of malapposition and self-correction. Directly after implantation, malapposition was detected by OCT with a maximum vessel-wall distance of 0.33 mm. After 15 minutes, malapposition was decreased and the maximum vessel-wall distance was 0.25 mm.

Acknowledgements

We would like to acknowledge the assistance of Elizabeth Martinson, PhD, for helpful editing and advice in the preparation of the manuscript.

Conflict of interest statement

H. Nef has received speaker’s honoraria from Elixir Medical. The other authors have no conflicts of interest to declare.

Online data supplement

Online Appendix. Sequence of baseline and procedural imaging.

Online Figure 1. Scaffold implantation using the marker-over-marker technique.

Online Figure 2. Post-dilatation with a non-compliant balloon.

Moving image 1. Baseline angiography.

Moving image 2. Baseline OCT.

Moving image 3. Predilatation with a non-compliant balloon.

Moving image 4. Predilatation with a scoring balloon.

Moving image 5. Final angiography.

Moving image 6. Final OCT.

Online Appendix. Sequence of baseline and procedural imaging

Baseline angiography revealed a stenosis of the mid-RCX and another of the ostial RCX (Moving image 1). Additional optical coherence tomography imaging confirmed the angiographic findings (Moving image 2).

Predilatation was performed with a non-compliant balloon (2.5/20 mm) (Moving image 3) and with a scoring balloon (2.5/10 mm) at the site of lesion (Moving image 4). A 2.5/28 mm DESolve 100 scaffold was implanted. Due to distal edge dissection a further 2.5/14 mm DESolve 100 was implanted distally. The ClearStent technology demonstrated that implantation was performed in a marker-over-marker technique (Online Figure 1). Post-dilatation was performed with a non-compliant balloon (Online Figure 2) and final angiography showed TIMI 3 flow and a reasonable result (Moving image 5), which was further confirmed by OCT (Moving image 6).

Online Figure 1. Scaffold implantation using the marker-over-marker technique.

Online Figure 2. Post-dilatation with a non-compliant balloon.

Volume 11 Number 2
Jun 19, 2015
Volume 11 Number 2
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00052 Mar 18, 2024
Comparative preclinical assessment of drug-coated balloons: a blessing and a curse for clinical translation
Joner M and Wild L
free

Debate

10.4244/EIJ-E-24-00005 Mar 18, 2024
Ischaemic and viability testing for guiding PCI are overrated: pros and cons
McEntegart M et al
free

Original Research

10.4244/EIJ-D-23-00725 Mar 18, 2024
A systematic algorithm for large-bore arterial access closure after TAVI: the TAVI-MultiCLOSE study
Rosseel L et al

Original Research

10.4244/EIJ-D-23-00783 Mar 18, 2024
Redo-TAVI with the ACURATE neo2 and Prime XL for balloon-expandable transcatheter heart valve failure
Meier D et al
Trending articles
281.88

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved